Skip to main content

Advertisement

Table 1 Age, sex, and disease duration since diagnosis

From: The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases

  Rheumatoid arthritisa Psoriatic arthritis Ankylosing spondylitis
  Placebo n = 450 IFX n = 1061 Placebo n = 100 IFX n = 100 Placebo n = 78 IFX n = 201
Sex, % women 82% 78% 49% 29% 13% 22%
Age (years)b 52.2 (12.3) 51.8 (12.4) 46.5 (11.3) 47.1 (12.8) 40.3 (9.4) 39.6 (10.6)
Range (19, 85) (18, 89) (24, 71) (18, 80) (20, 74) (18, 71)
Disease duration (years)b 9.9 (8.8) 10.3 (9.1) 7.5 (7.8) 8.4 (7.2) 11.9 (8.0) 10.1 (8.7)
Range (0.3, 41.5) (0.3, 55.5) (0.3, 38.5) (0.4, 29.2) (0.3, 31.6) (0.3, 41.1)
  1. aAll patients were receiving concomitant methotrexate; bValues are mean (standard deviation) unless otherwise indicated. IFX, infliximab.